Abstract-Interferon gamma (IFNg)-mediated activation of the myelomonocytic cell line HL-60 and peripheral blood monocytes will induce expression of an epitope for the monoclonal antibody which recognizes human aEb7 integrin, HML-1. Here, we found that the anti-human aEb7 monoclonal antibody Ber-ACT8 did not recognize IFNg-stimulated, HML-1 positive HL-60 cells. Culture of blood monocytes with IFNg also induced expression of HML-1 but not Ber-ACT8 epitopes. Moreover, migration of monocytes across a monolayer of human airway epithelial cells rapidly induced expression of HML-1, with no detectable Ber-ACT8 staining. Using two different sets of primers specific for the human aE integrin gene, we were unable to detect aE mRNA within HL-60 cells or isolated monocytes by reverse transcriptase polymerase chain reaction methods. We conclude that reactivity of the HML-1 antibody for HL-60 cells and monocytes does not correspond with the expression of the aE integrin subunit, and instead detects a marker for cellular activation.
INTRODUCTION
The differentiation of peripheral blood monocytes into tissue macrophages is accompanied by intracellular signaling events that alter adhesiveness, as well as oxygen radical production, and phagocytic functions. In vitro, monocytes can differentiate into a macrophage phenotype via stimulation with phorbol 12-myristate 13-acetate (PMA), or biological modifiers such as endotoxin and interferon gamma (IFNg) (1) (2) (3) . Both alveolar macrophages and phorbol-induced macrophages exhibit downregulation of a4, a6, a1, am, and b2 integrins, as compared with peripheral blood monocytes (4) . Activation of myeloid cell lines with either PMA or IFNg results in upregulation of the b7 integrin gene, as well as enhanced cell surface expression of the a4b7 integrin complex (5) . The pattern of integrins expressed during the process of monocyte differentiation into tissue macrophages may be important for trafficking to sites of inflammation by mediating strong adhesion to endothelium, as well as subsequent extravasation into the surrounding parencyhma.
In addition to the a4b7 integrin complex, the b7 subunit can also form a complex with the aE integrin. aEb7 integrin was originally identified by the monoclonal antibody HML-1 as a molecule localized on mucosal lymphocytes within the gastrointestinal tract (6) . Less than 1% of circulating blood lymphocytes express aEb7, whereas almost all intraepithelial lymphocytes express this integrin complex. There has been limited exploration of aEb7 integrin expression on other leukocyte phenotypes. Cell surface expression of aEb7 has not been detected on freshly isolated peripheral blood monocytes and granulocytes, however, several investigators have reported immunohistochemical reactivity of tissue macrophages to the anti-human aEb7 integrin monoclonal antibody, HML-1 (5, 7, 8) .
In a previous study using an in vitro model for leukocyte recruitment into the airways, we have demonstrated preferential, pertussis toxin sensitive migration of monocytes across an airway epithelial cell barrier (9) . In order to characterize the effect of transepithelial trafficking on monocyte activation (prior to alveolar macrophage differentiation), we have examined CD14 positive cells for reactivity to the HML-1 antibody. Although enhanced expression of the HML-1 epitope was observed on CD14 positive monocytes that migrate across airway epithelium, we made the surprising observation that transmigrated monocytes were not recognized by the anti-human aEb7 integrin monoclonal antibody, Ber-ACT8. HML-1 and Ber-ACT8 recognize different epitopes of aEb7, yet both antibodies immunoprecipitate proteins of identical molecular weight from HTLV-1 T cell lines or T lymphocytes activated in vitro (10, 11) . It has been reported that stimulation of human peripheral blood monocytes or the HL-60 human myelomonocytic cell line with eitehr IFNgor PMA results in surface expression of aEb7, as detected by the HML-1 monoclonal antibody (5) . In light of the aforementioned findings, in this current study we have reexamined the expression of aEb7 on IFNg-activated monocytes with respect to immunoreactivity of HML-1 and Ber-ACT8 monoclonal antibodies and investigated the molecular nature of the aE integrin subunit within HML-1 positive myeloid cells.
MATERIALS AND METHODS
Cells and Reagents. The human myelomonocytic cell line HL-60 was obtained from American Type Culture Collection (Manassas, Virginia). HL-60 cells were cultured in Teflon beakers with RPMI 1640 (Sigma, St. Louis, Missouri), supplemented with 10% fetal calf serum (Sigma) and 0.1 mM 1,25-Dihydroxyvitamin D 3 (Calbiochem, La Jolla, California) to induce a monocyte phenotye (12) . Peripheral blood mononuclear cells (PBMC) were obtained from healthy human volunteers, using density gradient sedimentation over Ficoll-Hypaque (Sigma). Freshly isolated PBMC were cultured in Teflon beakers with RPMI 1640, supplemented with 10% fetal calf serum. Peripheral blood monocytes were isolated by density gradient sedimentation of buffy coat over OptiPrep media (Sigma), as previously described by Graziani-Bowering and colleagues (13) . Recombinant human IFNg was purchased from Endogen (Woburn, Massachusetts). The human bronchial epithelial cell line BEAS-2B S.6 was a gift from Curtis Harris (Bethesda, Maryland). Cells (BEAS-2B S.6) were maintained in BEGM (Clonetics, Walkersville, Maryland).
The mouse-anti-human aEb7 integrin monoclonal antibody HML-1 (IgG2a) was obtained from Immunotech (Westbrook, Maine) (6) . The mouse anti-human aEb7 integrin monoclonal antibody BerACT8 (IgG1) obtained from DAKO (Carpinteria, California) (10) . Fluorescein (FITC) conjugated mouse anti-human CD14 (TÜK4), goat anti-mouse IgG phycoerythrin (PE) and goat antimouse IgG FITC were also purchased from DAKO.
Immunostaining and Flow Cytometry. Four-parameter analysis was performed on a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, California) with FITC and PE fluorochromes. For each test sample, 4-5 ×10 5 cells were stained; comparable numbers of cells were used for each test sample within an individual experiment. Immunofluorescence staining for multi-parameter analysis was performed as previously described (9) . For analysis by flow cytometry, data was acquired in list mode, acquiring 10,000-30,000 events per sample. Data was analyzed by CELLQuest software (Becton Dickinson Immunocytometry Systems). Analysis of monocytes was performed using a combination of a light scatter gate and a gate based on CD14 positive fluorescence. To eliminate potential contamination of epithelial cells in the analysis of migrated PBMC fractions within transmigration assays, a large gate was placed around the entire PBMC population as determined by forward and side light scatter properties. In some experiments, isolated blood monocytes stained for immunofluorescence were visualized by an epifluorescence microscope (OlympusProvis).
PBMC Transepithelial Migration Assay. PBMC transepithelial migration assays were performed as previously described (9) . Briefly, BEAS-2B S.6 airway epithelial cells were plated onto inverted 6.5 mm 3 mm pore Transwell polycarbonate membrane inserts (Costar, Cambridge, Massachusetts) and allowed to adhere. Following overnight incubation, Transwells were reversed to correct orientation for basolateral-to-apical surface migration and epithelial cells were allowed to proliferate until confluent. For migration assays, 1.5 ×10 6 freshly isolated PBMC were added to upper wells of culture inserts and allowed to incubate for 3 h at 37 C in 5% CO 2 . Fractions of PBMC within the upper well and lower well of each culture insert were separately collected prior to staining for flow cytometry.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis. Total RNA was extracted from cells using a single-step guanidinium thiocyanate-phenol-chloroform extraction reagent (GIBCO-BRL, Grand Island, New York). cDNA was synthesized from total RNA with Moloney Murine Leukemia Virus reverse transcriptase at 42 C (Clontech, Palo Alto, California). cDNA was amplified with Taq DNA polymerase (Boehringer Mannheim) using 10 mmol of each primer. PCR conditions were as follows: 94 C for 2 min, followed by 35 cycles of 94 C for 30 s, 60 C for 45 s then 68 C for 4 min, ending with 68 C for 7 min. The presence of intact RNA was checked in all samples by RT-PCR amplification of a 983 base pair segment from human glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mRNA using commercial primers (Glontech). Human aE integrin-specific PCR primers were designed based on a previously reported sequence (14) . Primers used were: P1: 5′-TGGCTCTTCCACACTCTGCTCTG-3′: P2: 5′-CGACCTTGAAAATCTCCTGG-3′: P3: 5′-GCAATCTCGGTGCCAGCTT-3′.
RESULTS

Effect of IFNg on Expression Ber-ACT8 Epitopes on Monocytic Cells.
It has been previously reported that cell surface expression of the aEb7 integrin complex may be upregulated on HL-60 cells and isolated peripheral blood monocytes following 72 h culture with IFNg (5). Expression of the aEb7 integrin complex was detected by these investigators with the mouse anti-human aEb7 integrin monoclonal antibody, HML-1. In a similar fashion, we have found enhanced expression of the HML-1 epitope(s) on HL-60 cells over IgG2a isotype controls in response to IFNg treatment ( Figure 1A ). In contrast, the mouse anti-human aEb7 monoclonal antibody, Ber-ACT8, did not appear to simultaneously detect the aEb7 integrin complex within HL-60 cultures. Although background fluorescence for mouse immunoglobulin isotype controls was slightly higher for IgG2a versus IgG1, primary antibody fluorescence for HML-1 was pronounced over controls, particularly in response to IFNg treatment. Within four independent experiments, expression of HML-1 was enhanced on average 4.2 fold (SEM ± 1.3) over control (untreated) cultures.
To determine if human peripheral blood monocytes can express a similar pattern of HML-1 versus Ber-ACT8 epitope expression, freshly isolated human PBMC were also cultured for 72 h prior to analysis by flow cytometry. As shown in Figure 1B , CD14 positive monocytes without IFNg treatment can express detectable levels of HML-1 epitopes, with no reactivity by Ber-ACT8. Within two separate experiments using two different blood donors, HML-1 expression was 32 and 44% with respect to isotype controls and minimal expression of Ber-ACT8. Addition of IFNg to PBMC cultures reduced expression levels of CD14 ( Figure 1C) ; as T lymphocytes can also express aEb7, we could not accurately confirm by flow cytometry if HML-1 antibody binding was strictly associated with the monocyte population. Using purified preparations of human peripheral blood monocytes, we were able to detect weak expression of CD14 on cells cultured with IFNg using immunofluorescence microscopy ( Figure 1C , panels a,b). As confirmed by flow cytometry, HML-1-specific fluorescence co-localized on CD14 positive cells, with no detectable expression of Ber-ACT8 epitopes ( Figure 1C, panels a-d) .
Effect of Transepithelial Migration on Expression of Ber-ACT8 and HML-1 Epitopes on Monocytes.
To determine if other potential pathways of monocyte activation can upregulate epitopes for HML-1 or Ber-ACT8, we allowed PBMC to migrate across a human airway epithelial cell monolayer within an established model of leukocyte transepithelial migration (9) . We have previously demonstrated that following a 3 h incubation with epithelial cell monolayers, monocytes preferentially transmigrate (in comparison with other PBMC subpopulations) and retain surface expression of CD14. The CD14 positive population within transmigrated PBMC exhibited a pronounced increase in HML-1 staining, in comparison with the starting population of PBMC (Figure 2 ). Although the non-migrated PBMC population was virtually depleted of monocytes, the remaining CD14 positive cells exhibited HML-1 immunofluorescence comparable to that of the starting population (data not shown). CD14 positive monocytes (A) HL-60 cells were cultured with 100 U / ml of IFNg for 72 h prior to analysis. Control cells had no cytokine during the culture period. HL-60 cells were incubated with either Ber-ACT8 or HML-1 antibodies, followed by a goat anti-mouse IgG PE secondary. Alternatively, cells were incubated with appropriate isotype controls for Ber-ACT8 (IgG1) or HML-1 (IgG2a), followed by goat antimouse IgG PE. Immunofluorescence staining was analyzed by flow cytometry. Histograms represent surface binding of antibodies from one representative experiment out of four completed. Values listed within the upper right hand corner of each histogram represent the percentage of PE positive cells above background (as measured by isotype controls). (B) PBMC were cultured for 72 h prior to analysis. Following culture, cells were incubated with either Ber-ACT8 or HML-1 antibodies, followed by goat anti-mouse IgG PE secondary, followed by anti-CD14 FITC. Alternatively, cells were incubated with appropriate isotype controls for Ber-ACT8 (IgG1) or HML-1 (IgG2a), followed by goat anti-mouse IgG PE, followed by anti-CD14 FITC. Immunofluorescence staining was measured by flow cytometry. CD14 positive cells were gated based on forward and side-light scatter as well as CD14 positive fluorescence. Histograms represent surface binding HML-1, Ber-ACT8, or PCR was performed on HL-60 cells and isolated peripheral blood monocytes cultured with IFNg. As it has been previously demonstrated that IFNg-activated HL-60 cells do express detectable levels of b7 integrin mRNA (5), the aE integrin subunit was the focus of analysis here. As would be expected from a cell population containing aEb7 positive T lymphocytes, primer pairs flanking the signal peptide sequence and unique X domain of the human aE integrin subunit amplified a 605 base pair fragment from PBMC RNA lane 1, top panel). In contrast, the 605 base pair cDNA fragment was not detected within RNA from isolated monocytes or HL-60 cells cultured with IFNg ( Figure 3A, lanes 2-3, top  panel) . As a control, RT-PCR using primers for G3PDH confirmed the integrity of RNA isolated from all cells used for aE integrin analysis ( Figure 3A, lanes Fig. 2. Effect of monocyte transepithelial migration on surface expression of Ber-ACT8 and HML-1 epitopes. 1.5 ×10 6 PBMC were added to upper wells of culture inserts containing confluent epithelial cell monolayers and incubated at 37 C in 5% CO 2 . Following a 3 h incubation, the PBMC starting population and fractions from lower wells of culture inserts were stained for flow cytometry using either HML-1 or Ber-ACT8 antibodies, followed by goat anti-mouse IgG PE secondary, followed by anti-CD14 FITC. Monocyte populations were gated based on forward and side light scatter and CD14 positive fluorescence. Histograms represent surface binding HML-1 or Ber-ACT8 antibodies on CD14 positive cells as measured by FACS analysis from one representative experiment out of three performed.
1-3, bottom panel). In addition, RT-PCR amplification of a 186 base pair region internal to the 605 base pair fragment (flanking the X domain) yielded a product from PBMC, but not HL-60 cells ( Figure 3B ).
DISCUSSION
The mouse monoclonal antibody HML-1 was the first of a series of immunological markers to be developed which selectively recognize the unique subpopulation of granular lymphocytes that intercalate within the epithelial lining of the human intestine. The HML-1 clone was generated by immunization with isolated human intestinal intraepithelial lymphocytes (IEL); immunohisto- chemical analysis have confirmed that the HML-1 antibody recognizes greater than 90% of human IEL and approximately 40% of lamina propria T lymphocytes within the intestine, but less than 1% of peripheral blood lymphocytes (6) . Subsequent biochemical analysis have demonstrated that the immunoprecipitated HML-1 antigen from human IEL consists of 175 kDa and a 105 kDa fragments, characterized as the aE and b7 integrin subunits, respectively (6, 15) . The HML-1 monoclonal antibody also recognizes IEL from other mucosa, including the conducting airways, as well as a subset of intestinal T cell lymphomas (16, 17) . Several reports have observed HML-1 reactivity in T cell lymphomas of cutaneous origin, as well has specific staining of activated macrophages, leading to speculation with regards to the specificity of this monoclonal activity (7, 8) .
Tiisala and colleagues have previously shown that treatment of HL-60 cells and peripheral blood monocytes with IFNg can induce surface reactivity for the HML-1 clone, suggesting that activated monocytes / macrophages express the aEb7 integrin complex (5) . In this current study, we have found that a different anti-human aEb7 mouse monoclonal antibody (Ber-ACT8) did not recognize IFNg-stimulated, HML-1 positive HL-60 cells. Culture of blood monocytes with IFNg also induced surface expression of HML-1 but not Ber-ACT8 epitopes. Finally, transmigration of monocytes across a human airway epithelial cell bar-rier surface rapidly induced surface expression of HML-1, with no detectable staining using the Ber-ACT8 clone. Histologically, both Ber-ACT8 and HML-1 clones have overlapping localized staining patterns for T lymphocytes, suggesting that the antigens recognized are comparable (10) . Moreover, immunoprecipitation of an HTLV T cell line or in vitro activated T cells with either monoclonal antibody yields protein fragments of identical molecular weight (10, 11) . Although we have not been able to demonstrate Ber-ACT8 reactivity on activated monocytes / macrophages above that observed with isotype controls, Kruschwitz and colleagues have reported faint staining of tissue macrophages with the Ber-ACT8 clone (10) . The source of this apparent discrepancy is not clear, however we did find that despite our efforts to block nonspecific binding, the IgG1 isotype control for Ber-ACT8 produced a significant amount of background reactivity.
To the best of our knowledge, the biochemical or molecular nature of the HML-1 antigen has not been fully characterized in activated monocytes / macrophages. Expression of mRNA for the b7 integrin subunit of aEb7 has been reported for activated monocytes. However, the b7 integrin subunit can also form a complex with the a4 integrin subunit; indeed, surface expression of a4b7 has been detected on in vitro activated monocytes (5) . As such, in this report we evaluated expression of the aE integrin subunit mRNA by RT-PCR methods.
Using two different nested sets of primers specific for the human aE integrin gene, we were unable to detect aE mRNA within IFNg-stimulated myeloid cells.
Immunoprecipitation of the HML-1 antigen from HL-60 cells did not result in discernable protein fragments, suggesting that the antibody-ligand interaction is weak.
Based on these findings, we conclude that detection of the HML-1 epitope on HL-60 cells and peripheral blood monocytes does not correspond with expression of the aE integrin subunit. Given the association of HML-1 reactivity with monocytes activated in vitro and tissue macrophages, these findings instead point to an alternative, cross-reactive epitope that defines a cellular marker of activation. Importantly, these data strongly suggest cautious interpretation of HML-1 immunoreactivity, particularly with regards to expression of the aEb7 integrin complex and functional assessment of leukocytes. As yet we do not know if all T lymphocytes which are recognized by the HML-1 antibody express aEb7; future double labeling studies with other anti-aEb7 antibodies should allow for this determination.
